Certara

Certara, founded in 2008, is a leading provider of software, AI-driven platforms, and scientific consulting services dedicated to optimizing drug development. The company's expertise lies in model-informed drug development (MIDD) and advanced biosimulation technologies, enabling pharmaceutical and biotechnology firms to predict drug behavior and enhance clinical outcomes. With a significant global footprint, Certara supports clients worldwide in navigating the complex journey from drug discovery through to market access. Learn about Certara's global headquarters for insights into its operational reach.

Operating across the entire drug development lifecycle, Certara offers solutions for discovery, preclinical modeling, clinical trials, regulatory submissions, and market access strategies. Its comprehensive suite of products and services, including its renowned biosimulation tools, empowers researchers and developers to make informed decisions, accelerate timelines, and reduce the risks associated with bringing new therapies to patients. The company employs a dedicated team of scientists and experts, contributing to its robust capabilities. Meet Certara's team to understand the depth of scientific acumen driving its innovations.

Certara reported revenue of $419.7M, underscoring its substantial market presence. The company operates with 1,000-5,000 employees across 31 locations, positioning it as a significant player in the life sciences technology sector. It competes with various firms in the drug development software and services space, focusing on delivering value through scientific rigor and technological advancement. For detailed financial performance and metrics, users can Explore financial highlights. Certara's commitment to advancing medicine through data-driven insights solidifies its role in the biopharmaceutical ecosystem.